<DOC>
	<DOCNO>NCT00487058</DOCNO>
	<brief_summary>This study assess tolerability , safety , efficacy pharmacokinetics gimatecan Japanese patient . Gimatecan administer orally twice per week , every 28 day , adult patient advance solid tumor progress despite standard therapy standard systemic therapy dose exist .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study LBQ707 ( Gimatecan ) Administered Orally Twice Per Week Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion Patients histological cytological confirm advanced solid tumor , progress despite standard therapy standard therapy exist Life expectancy least 3 month No dysfunction bone marrow No major impairment renal hepatic function Exclusion criterion Gastrointestinal dysfunction , gastrectomy malabsorption syndrome , could alter absorption study drug Receipt investigational compound within 28 day prior first dose study drug , failure recover side effect prior therapy Receipt antineoplastic therapy include chemotherapy , hormone therapy , immunotherapy , radiation therapy within 28 day Patients known HIV , hepatitis B C viruses positive , patient presence active suspect acute chronic uncontrolled infection Patients history allergy camptothecin family drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Gimatecan</keyword>
	<keyword>topoisomerase I inhibitor</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>